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Background  3 
Dried blood spot (DBS) testing for hepatitis C (HCV) was introduced to Scotland in 4 
2009. This minimally invasive specimen provides an alternative to venipuncture and 5 
can overcome barriers to testing in people who inject drugs (PWID). 6 
Objectives  7 
The objective of this study was to determine rates and predictors of: exposure to 8 
HCV, attendance at specialist clinics and anti-viral treatment initiation among the 9 
DBS tested population in Scotland.   10 
Study design  11 
DBS testing records were deterministically linked to the Scottish HCV Clinical 12 
database prior to logistic regression analysis. 13 
Results  14 
In the first two years of usage in Scotland, 1322 individuals were tested by DBS of 15 
which 476 were found to have an active HCV infection. Linkage analysis showed that 16 
32% had attended a specialist clinic within 12 months of their specimen collection 17 
date and 18% had begun anti-viral therapy within 18 months of their specimen 18 
collection date. A significantly reduced likelihood of attendance at a specialist clinic 19 
was evident amongst younger individuals (<35 years), those of unknown ethnic origin 20 
and those not reporting injecting drug use as a risk factor.  21 
Conclusion 22 
We conclude that DBS testing in non-clinical settings has the potential to increase 23 





In Scotland, 0.8% of the population aged 15-59 years had been diagnosed with 28 
hepatitis C virus (HCV) antibodies by the end of 2012 [1].  The majority of these 29 
infections occur in individuals with a history of injecting drug use [2] and recent 30 
estimates suggest that around half of people infected with HCV remain undiagnosed 31 
[1].  To tackle the epidemic of HCV in Scotland, the Hepatitis C Action Plan for 32 
Scotland was launched in September 2006 [3].  In its initial Phase (September 2006 – 33 
March 2008) the Action Plan identified poor venous access amongst people who 34 
inject drugs (PWID), along with a shortage of trained phlebotomists, and the long 35 
interval between testing and return of results, as barriers to testing and diagnosis of 36 
HCV in this population [4].  Dried blood spots (DBS), drops of whole blood from a 37 
finger prick dried onto filter paper, provide an alternative to whole blood specimens 38 
collected by venipuncture and can overcome the majority of barriers to HCV testing 39 
outlined above [5,6,7,8].  As a result of the Action Plan, DBS testing for HCV 40 
diagnosis was introduced in Scotland in May 2009.  Now that DBS testing is well 41 
established in Scotland, the outcomes of DBS testing are quantifiable to give a better 42 




The objective of this study was to determine the proportion of those tested by DBS in 47 
Scotland who had been exposed to HCV; of those diagnosed as being currently 48 
infected with HCV the proportion attending a specialist clinic and, of those, the 49 
proportion who were initiated on anti-viral treatment.  Epidemiological information 50 
 3 
collected alongside the DBS specimens is also analysed to identify predictors of 51 
exposure, attendance and treatment initiation amongst this population.   52 
 4 
Study Design 53 
 54 
Data Sources and Linkage 55 
The Scottish Hepatitis C Clinical Database, held at Health Protection Scotland (HPS), 56 
contains clinical follow-up data for HCV-infected patients attending 17 specialist 57 
clinics across Scotland.  These data include attendance dates, treatment episodes, 58 
demographic, clinical, virological, and patient identifiers (date of birth, sex, surname 59 
Soundex (a consonant-only phonetic encoding), and forename initial).  Data were 60 
restricted to individuals on the database on 31 December 2012 and at this date the 61 
database contained records for 14,298 individuals with sufficient identifiers for 62 
linkage. 63 
 64 
HPS also maintains records on all DBS testing in Scotland since May 2009.  The DBS 65 
database contains information on dates and result(s) of HCV antibody and reverse 66 
transcriptase polymerase chain reaction (RT-PCR) testing, source, ethnicity, risk 67 
activitie(s), length of injecting career and limited identifying information (i.e., date of 68 
birth, sex, surname Soundex and forename initial).  On 31 December 2010 this 69 
database comprised records for 1448 specimens relating to 1322 individuals. 70 
 71 
Records from the DBS database (up to 31 December 2010) were deterministically 72 
linked to individuals on the HCV Clinical database (to 31 December 2012); a 73 
complete match on surname Soundex, gender, DOB, and first initial was required for 74 




Data Analysis   78 
Three main outcomes were analysed: (a) anti-HCV positivity amongst all individuals 79 
tested by DBS for HCV since the inception of the DBS testing programme in Scotland 80 
(May 2009) to 31 December 2010, (b) first clinic attendance amongst all chronically 81 
HCV-infected persons recorded as being tested by DBS for HCV infection between 82 
May 2009 and 31 December 2010 and (c) initiation on antiviral therapy amongst the 83 
chronically HCV-infected patients attending a specialist clinic.  Univariate and 84 
multivariate logistic regression modelling was used to examine the association 85 
between the covariates sex, age at diagnosis (grouped into < 35years, ≥ 35years), 86 
ethnicity (White, Unknown/Non-white), Source of DBS (Community Addiction 87 
Team/Harm Reduction, Other) and time since onset of injecting (≤10years, > 10years, 88 
Not Known (PWID), Non-PWID) and the outcomes: ‘HCV antibody positive’ (Table 89 
1), ‘first clinic attendance within 12 months of diagnosis by DBS’ (Table 2) and 90 
‘initiation on antiviral therapy within 18 months of DBS specimen collection’ (Table 91 
3).  For the latter analysis the variable ‘Risk Factor’ (Current PWID, Past PWID, 92 
Non-PWID/Unknown) was also included.  For the Risk Factor variable data collected 93 
on length of injecting career (including age of first and last injection) was used, where 94 
available, to categorise individuals as past PWID and present PWID, with any 95 
individual giving a date of last injecting drug use as five or more years prior to the 96 
DBS specimen collection date classified as a past PWID.    97 
 98 
All analysis was carried out in R 3.0.1 [8]. Exact p-values are provided except where 99 
P< 0.001.   100 
 6 
Results  101 
 102 
In 2009/10 DBS specimens were collected from 1322 individuals in Scotland for 103 
HCV screening.  Of these individuals 55% (n=728) were seropositive for antibody to 104 
HCV, and approximately two-thirds (65.4% (n=476)) had an active HCV infection 105 
(Figure 1).  Table 1 presents characteristics of the overall study sample, according to 106 
HCV antibody prevalence. The majority (70%) were males, although HCV antibody 107 
prevalence in both sexes was equal at 55%.  The average age of all DBS tested 108 
individuals was 36, with 45% of individuals falling into the < 35yrs age category and 109 
55% into the ≥ 35yrs category.  Antibody prevalence was significantly higher in the 110 
older age category compared to the younger; 64% (95% CI: 60 – 67%) and 45% (95% 111 
CI: 41 – 49%) respectively.  White was the main ethnicity (82.8%), the remainder 112 
being of unknown (16.5%) or non-white (0.7%) ethnicity.  Most individuals (89.3%) 113 
were tested in a community addiction team or harm reduction setting as opposed to 114 
other settings (hospital (3.8%), GP (1.7%), prison (0.6%) or private (4.6%)).   115 
 116 
Odds of HCV antibody  117 
Multifactorial logistic regression analysis found age to be related to odds of antibody 118 
positivity, with those aged ≥ 35 years significantly more likely (AOR=1.93, 95% 119 
CI:1.51 – 2.47) than those aged < 35 years to be antibody positive.  The adjusted odds 120 
ratio of ethnicity was also positively associated with prevalence. Individuals who 121 
were recorded as being of white ethnic origin being more likely (AOR=2.00, 95% CI: 122 
1.42 – 2.85) to be antibody positive as those of unknown/non-white ethnic origin.   123 
 124 
 7 
PWID are well known to be at increased risk of infection with hepatitis C, particularly 125 
those with longer injecting histories.  The majority of individuals (85.6%) tested by 126 
DBS reported being/having been a PWID; those who did not report injecting drug use 127 
as a risk factor were less likely to be  antibody positive (AOR=0.28, 95% CI: 0.17 – 128 
0.39) than those who had commenced injecting in the previous ten years.  There was a 129 
marked increase in prevalence between individuals who had injected for 10 years or 130 
less (46.8%) and individuals with injecting histories of over 10 years (80.0%).  This 131 
translated into a 3.6-fold increased odds of HCV exposure for the individuals with 132 
injecting histories of over a decade (AOR=3.58, 95% CI: 2.36 – 5.45) in the adjusted 133 
analysis.   Finally, although not significant in the multifactorial analysis, individuals 134 
tested in a community addiction clinic/harm reduction setting (n=1180) were more 135 
likely (OR=1.84. 95% CI: 1.30 – 2.63) to be positive for antibody to HCV as those 136 
tested in other settings in the univariate analysis (Table 1).   137 
 138 
Attendance at Specialist Hepatitis Clinics within 12 months of DBS specimen. 139 
Of the 728 individuals known to be antibody positive there were 476 (65.4%) 140 
individuals with an active HCV infection as confirmed by RT-PCR.  Linkage of these 141 
individuals to the Hepatitis C Clinical Database showed that 202 (42.4%) had ever 142 
attended a specialist hepatitis clinic, and 31.9% (n=152) within 12 months following 143 
collection of their DBS specimen (Figure 1).  For 7.8% (n=37) of individuals a date of 144 
attendance prior to the DBS specimen date was also found.   145 
 146 
Univariate analysis did not show any significant relationship between the likelihood 147 
of attendance at a specialist hepatitis clinic within the twelve months following 148 
diagnosis by DBS and any of the examined variables.  However, multifactorial 149 
 8 
logistic regression found a significant relationship between age, risk factor status and 150 
ethnicity and attendance at a specialist clinic within 12 months.  Individuals aged 35 151 
or older were more likely (AOR=1.49, 95% CI: 1.05-2.13) than those aged <35 years 152 
to attend a treatment clinic within 12 months of DBS diagnosis.  Individuals who were 153 
recorded as being of a white ethnic background were also more likely (AOR=2.85, 154 
95% CI: 1.57-5.58) to attend a clinic within 12 months as those of a unknown/non-155 
white ethnic background, and there was also a significantly reduced likelihood 156 
(AOR=0.32, 95% CI: 0.13 – 0.71) of attendance at a clinic within 12 months for 157 
individuals with a non-PWID risk factor (Table 2).  158 
 159 
Initiation on anti-viral therapy within 18 months of DBS specimen date 160 
Of the 202 individuals recorded as attending a specialist hepatitis clinic following 161 
collection of a DBS specimen in 2009/10, 66 individuals (32.7%) were recorded 162 
beginning anti-viral therapy up to the end of 2012.  For 18.3% (n=37) of individuals 163 
anti-viral therapy was commenced within 18 months of having the DBS specimen 164 
collected (Figure 1).  Following logistic regression analysis there was no significant 165 
association with the likelihood of receiving treatment within 18 months post DBS 166 




Previous studies have demonstrated the effectiveness of DBS in terms of test uptake 170 
amongst PWID [5,6,7,8].  To our knowledge, this is the first study to report on the 171 
performance of DBS testing in terms of attendance at specialist clinics and treatment 172 
initiation. Overall, we found that of the 476 individuals with active HCV infection, 173 
tested by DBS in 2009 and 2010, 31.9% had attended a specialist clinic within 12 174 
months of their specimen collection date and, of these, 18.3% had begun anti-viral 175 
therapy within 18 months of their specimen collection date.   176 
 177 
To understand how these figures compare to overall HCV diagnosis in Scotland we 178 
can relate our findings to a recent analysis which reviewed similar outcomes, across 179 
an overlapping time period, in all new HCV diagnoses in Scotland from 1996 180 
onwards.  The authors report that, of the 1364 individuals newly diagnosed with 181 
chronic HCV in Phase II of the Scottish Hepatitis C Action Plan (1 May 2008 to 31 182 
December 2010), 44.5% attended a specialist hepatitis clinic within 12 months of 183 
being diagnosed and 32% were initiated on anti-viral treatment within the 12 month 184 
period following first clinic attendance [10]. Comparing these figures shows that 185 
attendance at specialist hepatitis clinics is lower in the DBS tested population at the 186 
12 month follow-up point (31.9%) and, although not directly comparable, there also 187 
appear to be lower rates of initiation onto anti-viral therapy in the DBS tested 188 
population.  The populations are not entirely analogous, most notable is that the 189 
McDonald et al (2013) study included only new HCV diagnoses whereas this analysis 190 
included all diagnoses; among whom there was evidence of prior engagement with 191 
specialist services (Figure 1).  Since prior knowledge of HCV status may influence 192 
 10 
the probability of attendance and treatment this may account for some of the variation 193 
between the studies.  Finally, in our population, of those chronically infected with 194 
HCV, 95.4% reported having been/being a PWID and 92.6% were tested at a 195 
drug/counselling clinic, compared to 41.9% and 9.7% of the newly diagnosed 196 
population.  Thus the DBS diagnosed population may well represent a more chaotic 197 
group of individuals, involving those who continue to use and inject drugs, which 198 
would help to explain the poorer attendance and treatment outcomes amongst this 199 
population. Treatment of current PWIDs is still considered problematic by some 200 
medical professionals due to concerns over adherence to treatment regimes, medical 201 
and psychiatric co-morbidities, psychosocial issues and risk of re-infection [11].  202 
However, there is growing evidence to show that, given adequate support, good 203 
treatment outcomes can be achieved among people who continue to inject drugs 204 
[12,13].   205 
 206 
Looking within our DBS-tested population, logistic regression analysis showed that 207 
attendance at specialist hepatitis clinics within 12 months of the DBS specimen 208 
collection date was significantly reduced amongst individuals aged less than 35 years 209 
and those of unknown/non-white ethnic origin.  The significance of the latter finding  210 
is unclear as the majority (>98%) of individuals in this category were of unknown 211 
ethnicity. We also found that those in the non-PWID risk factor category are 212 
significantly less likely to attend a clinic within 12 months of their DBS collection 213 
date, despite being chronically infected with HCV.  The basis of this difference is 214 
unclear but may reflect the high proportion of PWID in our study and the emphasis of 215 
this risk factor amongst healthcare professionals working in DBS testing settings. 216 
Awareness of these demographic trends amongst healthcare professionals may enable 217 
 11 
targeted post-test discussion.  This analysis did not find any significant association 218 
between the variables examined and the likelihood of treatment initiation which may 219 
be due to the small sample size and, additionally, our analysis did not have the scope 220 
to include the physical, psychological and social factors involved in the decision to 221 
treat individuals, and/or willingness to undergo treatment, which have been found to 222 
be significant in other studies [14, 15,16]. 223 
 224 
DBS testing was recently estimated to be cost-effective in addiction services settings 225 
in the UK at an estimated £14,600 per quality adjusted life year (QALY) gained [17].  226 
The model was based on 35% of PWID being successfully referred from testing 227 
services to secondary care and 5.5% of referred PWID being treated within 2 years.  228 
The latter variable was based on the assumption that 1% of infected PWID are treated 229 
within 2 years, or 5.5% of those who attended referral. The authors note that the 230 
treatment parameter was a critical factor in assessing the cost-effectiveness of DBS 231 
testing since higher treatment rates prevent disease transmission thereby increasing 232 
the cost-effectiveness of case-finding interventions.  Whilst referral rates in our study 233 
are similar to those estimated in the model, we have found a much higher proportion 234 
of individuals in secondary care being treated; up to a third within 4 years of their 235 
DBS specimen and 18% within 18 months of their DBS specimen.  Although a 236 
proportion of our sample were determined to be past-PWID, for whom treatment rates 237 
are higher, 86.2% of the PWID with an active HCV infection had injected within the 238 
past five years.  As such these findings have great bearing on the cost-effectiveness of 239 
DBS testing which was estimated to drop to £4500 per QALY if 50% of referred 240 
PWID initiated treatment within 2 years [17].  241 
 242 
 12 
Our findings are further evidence of the utility of DBS testing in reaching the 243 
populations most at risk from HCV infection and engaging them with specialist 244 
hepatitis services.  Recent advances in HCV treatment, with the introduction of triple 245 
therapy as a standard treatment regime, has significantly improved the rates of 246 
sustained virological response [18] and the prospect of interferon-free treatment 247 
regimens makes the possibility of an all-oral therapy for HCV conceivable [19,20].  248 
Such advances will make treatment a more tolerable therapy and also open the 249 
possibility of treatment in the community setting; both of which may facilitate greater 250 
uptake in the DBS-tested population in the future.  In anticipation of these changes in 251 
HCV therapy, and the accompanying possibilities for treatment expansion, the use of 252 
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